EGFR and glioblastoma: Erlotinib, another EGFR inhibitor, was tested in combination with RT and TMZ with conflicting results in primary glioblastoma [130,131,132,133], and some beneficial outcomes in recurrent glioblastoma [134,135,136,137,138,139,140,141,142].